(thirdQuint)Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery.

 OBJECTIVES: - Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer.

 - Characterize the dose and tolerability of octreotide in this patient population.

 OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5.

 Patients who respond well to study may continue octreotide for palliative effects.

 PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.

.

 Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery@highlight

RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably.

 PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.

